Plasma active matrix metalloproteinase 9 associated to diastolic dysfunction in patients with coronary artery disease

International Journal of Cardiology

Volumn 147, Issue 2, 2011, Pages 336-338

  Chu, John W ^a   Jones, Gregory T ^a   Tarr, Gregory P ^a   Phillips, L Vicky ^a   Wilkins, Gerard T ^a   Van Rij, Andre M ^a   Williams, Michael J A ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Coronary artery disease; Diastolic function; Extracellular matrix; Matrix metalloproteinase

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GELATINASE A; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERSTITIAL COLLAGENASE; NITRATE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; CORONARY ARTERY DISEASE; DIASTOLIC DYSFUNCTION; DISEASE SEVERITY; DOPPLER ECHOGRAPHY; ENZYME BLOOD LEVEL; FEMALE; HEART HEMODYNAMICS; HUMAN; LETTER; M MODE ECHOCARDIOGRAPHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TRANSTHORACIC ECHOCARDIOGRAPHY;

EID: 79951943108     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2010.12.093     Document Type: Article

References (10)

1. Saglam M, Karakaya O, Esen AM, et al. Contribution of plasma matrix metalloproteinases to development of left ventricular hypertrophy and diastolic dysfunction in hypertensive subjects. Tohoku J Exp Med 2006;208:117-22. (Pubitemid 43174163)
2. Ahmed SH, Clark LL, Pennington WR, et al. Matrix metalloproteinases/ tissue inhibitors of metalloproteinases: Relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006;113:2089-96.
3. Castellazzi M, Tamborino C, Fainardi E, et al. Effects of anticoagulants on the activity of gelatinases. Clin Biochem 2007;40:1272-6. (Pubitemid 47562429)
4. Quinones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA. Recommendations for quantification of Doppler echocardiography: A report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr 2002;15:167-84.
5. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-63. (Pubitemid 41821197)
6. Rakowski H, Appleton C, Chan KL, et al. Canadian consensus recommendations for the measurement and reporting of diastolic dysfunction by echocardiography: From the Investigators of Consensus on Diastolic Dysfunction by Echocardiography. J Am Soc Echocardiogr 1996;9:736-60.
7. Yamada H, Goh PP, Sun JP, et al. Prevalence of left ventricular diastolic dysfunction by Doppler echocardiography: Clinical application of the Canadian Consensus Guidelines. J Am Soc Echocardiogr 2002;15:1238-44. (Pubitemid 36528731)
8. Cook NR, Buring JE, Ridker PM. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med 2006;145:21-9. (Pubitemid 46780601)
9. Kramar A, Faraggi D, Fortune A, Reiser B. mROC: A computer program for combining tumour markers in predicting disease states. Comput Meth Programs Biomed 2001;66:199-207. (Pubitemid 32707890)
10. Shewan LG and Coats AJ. Ethics in the authorship and publishing of scientific articles. Int J Cardiol 2010;144:1-2.